WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, November 22, 2004

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ	
☐	L11	L7.clm.	10
☐	L10	L8.clm.	2
☐	L9	L8.clm.	2
☐	L8	L7 same (screen$ or modulat$ or identif$)	217
☐	L7	l2 same (growth$ or proliferation or apoptosis or death)	671
☐	L6	l2 (s) (growth$ or proliferation or apoptosis or death)	0
		DB=USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ	
☐	L5	L4.clm.	3
☐	L4	L2 same (screen$ or identif$)	66
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ	
☐	L3	L2 same (screen$ or identif$)	384
☐	L2	Perlecan or HSPG or syndecan or glypican	1261
☐	L1	PILLARISETTI-SIVARAM.in.	23

END OF SEARCH HISTORY

h e b b cg b chh e c f f c e h

National Library of Medicine

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for hurt-camejo 1997 Preview Go Cle

Limits Preview/Index **History** Clipboard Details

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Search	Most Recent Queries	Time	Result
#18	Search **hurt-camejo 1997**	09:43:54	6
#17	Search **hurt cameio 1997**	09:43:41	120
#10	**Related Articles** for **PubMed** (Select **10593935**)	09:07:33	289
#9	Search **pillarisetti 36403**	09:06:15	1
#7	Search **Pillarisetti 36403**	08:30:39	1
#4	**Related Articles** for **PubMed** (Select **9496392**)	08:20:11	221
#1	Search **Adatia 1257**	07:59:45	1

Clear History

h cb h g e e e fcg b e

```
=> d his

     (FILE 'HOME' ENTERED AT 09:55:47 ON 22 NOV 2004)

     FILE 'DISSABS, 1MOBILITY, AGRICOLA, AQUASCI, BIOTECHNO, COMPENDEX,
     COMPUAB, CONF, CONFSCI, ELCOM, HEALSAFE, IMSDRUGCONF, LIFESCI, MEDICONF,
     OCEAN, PAPERCHEM2, PASCAL, POLLUAB, SOLIDSTATE, ADISCTI, ADISINSIGHT,
     ADISNEWS, ANABSTR, ANTE, AQUALINE, BIOBUSINESS, ...' ENTERED AT 09:56:06
     ON 22 NOV 2004
               E PILLARISETTI SIVARAM ?/AU
L1           130 S E1 OR E2 OR E3
L2         22718 S PERLECAN OR HSPG OR SYNDECAN OR GLYPICAN
L3            52 S L1 AND L2
L4            27 DUP REM L3 (25 DUPLICATES REMOVED)

     FILE 'STNGUIDE' ENTERED AT 10:11:25 ON 22 NOV 2004

     FILE 'DISSABS, 1MOBILITY, AGRICOLA, AQUASCI, BIOTECHNO, COMPENDEX,
     COMPUAB, CONF, CONFSCI, ELCOM, HEALSAFE, IMSDRUGCONF, LIFESCI, MEDICONF,
     OCEAN, PAPERCHEM2, PASCAL, POLLUAB, SOLIDSTATE, ADISCTI, ADISINSIGHT,
     ADISNEWS, ANABSTR, ANTE, AQUALINE, BIOBUSINESS, ...' ENTERED AT 10:26:44
     ON 22 NOV 2004
L5          8520 S L2 (S) (GROWTH? OR PROLIFERAT? OR ANTIPROLIFER? OR DEATH OR
L6          2352 S L5 (S) (IDENTIF? OR SCREEN? OR MODULAT?)
L7            88 S L6 (S) PRODUCTION
L8            49 DUP REM L7 (39 DUPLICATES REMOVED)

=>
```

L8 ANSWER 39 OF 49 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE

ACCESSION NUMBER: 1993:23239744 BIOTECHNO
TITLE: Novel neurite growth-inhibitory properties of an astrocyte proteoglycan
AUTHOR: Guo M.; Dow K.E.; Kisilevsky R.; Riopelle R.J.
CORPORATE SOURCE: Doran 2, Kingston General Hospital,Kingston, Ont. K7L 2V7, Canada.
SOURCE: Journal of Chemical Neuroanatomy, (1993), 6/4 (239-245)
CODEN: JCNAEE ISSN: 0891-0618
DOCUMENT TYPE: Journal; Article
COUNTRY: United Kingdom
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Conditioned medium (CM) of primary cultures of GFAP-positive adherent astrocytes from neonatal rat neocortex contained a chondroitin sulphate/dermatan sulphate proteoglycan (CDSPG) that co-eluted with a heparan sulphate proteoglycan (**HSPG**) by ion-exchange chromatography. The CDSPG was resolved from the **HSPG** by molecular sieve chromatography, which indicated that the molecular mass of the **HSPG** was greater than 300 kDa, while that of the CDSPG was approximately 50 kDa. Specific lyase digestion and urea/polyacrylamide gel electrophoresis established the ;homogeneity of the CDSPG and suggested molecular masses of the core protein and glycosylated protein as 54 kDa and 58 kDa respectively. Virtually all of the poly-D-lysine substrate-bound proteoglycan-associated neurite **growth**-promoting activity of astrocyte CM was accounted for by the **HSPG**. On poly-D-lysine the immobilized CDSPG displayed little neurite **growth**-stimulatory activity relative to the **HSPG**. However, the CDSPG inhibited the potent **growth** -promoting activity of the **HSPG** by displacing it from the poly-D-lysine substrate. Differential cellular regulation of **production** of **growth-modulatory** proteins with different binding avidity for the substrate of **growth** may determine the success of a regenerative axonal response by fully competent neurons.

AB. . . adherent astrocytes from neonatal rat neocortex contained a chondroitin sulphate/dermatan sulphate proteoglycan (CDSPG) that co-eluted with a heparan sulphate proteoglycan (**HSPG**) by ion-exchange chromatography. The CDSPG was resolved from the **HSPG** by molecular sieve chromatography, which indicated that the molecular mass of the **HSPG** was greater than 300 kDa, while that of the CDSPG was approximately 50 kDa. Specific lyase digestion and urea/polyacrylamide gel. . . core protein and glycosylated protein as 54 kDa and 58 kDa respectively. Virtually all of the poly-D-lysine substrate-bound proteoglycan-associated neurite **growth** -promoting activity of astrocyte CM was accounted for by the **HSPG** . On poly-D-lysine the immobilized CDSPG displayed little neurite **growth**-stimulatory activity relative to the **HSPG**. However, the CDSPG inhibited the potent **growth**-promoting activity of the **HSPG** by displacing it from the poly-D-lysine substrate. Differential cellular regulation of **production** of **growth-modulatory** proteins with different binding avidity for the substrate of **growth** may determine the success of a regenerative axonal response by fully competent neurons.

L4 ANSWER 24 OF 27 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

ACCESSION NUMBER: 2000:20752 BIOSIS
DOCUMENT NUMBER: PREV200000020752
TITLE: **Perlecan**, heparan sulfate proteoglycan, mediates the anti-proliferative effect of apolipoprotein E: An underlying mechanism for the modulation of smooth muscle cell growth?.
AUTHOR(S): Paka, Latha [Reprint author]; Obunike, Joseph C.; Choi, Sungshin Y.; **Pillarisetti, Sivaram**
CORPORATE SOURCE: North Shore - Long Island Jewish Health System, Manhasset, NY, USA
SOURCE: Circulation, (Nov. 2, 1999) Vol. 100, No. 18 SUPPL., pp. I.548. print.
Meeting Info.: 72nd Scientific Sessions of the American Heart Association. Atlanta, Georgia, USA. November 7-10, 1999.
CODEN: CIRCAZ. ISSN: 0009-7322.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 29 Dec 1999
Last Updated on STN: 31 Dec 2001

TI **Perlecan**, heparan sulfate proteoglycan, mediates the anti-proliferative effect of apolipoprotein E: An underlying mechanism for the modulation of smooth muscle cell. . .

AU Paka, Latha [Reprint author]; Obunike, Joseph C.; Choi, Sungshin Y.; **Pillarisetti, Sivaram**

IT . . .
regulation

IT Chemicals & Biochemicals
apolipoprotein E: antiproliferative effects, heparan sulfate proteoglycan mediation, smooth muscle cell expression; heparan sulfate proteoglycan [**perlecan**]: cell proliferation regulator, smooth muscle cell expression

ANSWER 27 OF 27 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 18

ACCESSION NUMBER: 1997:434240 BIOSIS
DOCUMENT NUMBER: PREV199799733443
TITLE: Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix.
AUTHOR(S): **Pillarisetti, Sivaram** [Reprint author]; Paka, Latha; Obunike, Joseph C.; Berglund, Lars; Goldberg, Ira J.
CORPORATE SOURCE: Dep. Med., Columbia Univ. Coll. Physicians Surgeons, BB 901, 630 West 168th St., New York, NY 10032, USA
SOURCE: Journal of Clinical Investigation, (1997) Vol. 100, No. 4, pp. 867-874.
CODEN: JCINAO. ISSN: 0021-9738.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 8 Oct 1997
Last Updated on STN: 8 Oct 1997

AB Vessel wall subendothelial extracellular matrix, a dense mesh formed of collagens, fibronectin, laminin, and proteoglycans, has important roles in lipid and lipoprotein retention and cell adhesion. In atherosclerosis, vessel wall heparan sulfate proteoglycans (**HSPG**) are decreased and we therefore tested whether selective loss of **HSPG** affects lipoprotein retention. A matrix synthesized by aortic endothelial cells and a commercially available matrix (Matrigel; Becton Dickinson Inc., Rutherford, NJ) were used. Treatment of matrix with heparinase/heparitinase (1 U/ml each) increased LDL binding by apprx 1.5-fold. Binding of lipoprotein (a) (Lp(a)) to both subendothelial matrix and Matrigel increased 2-10-fold when the **HSPG** were removed by heparinase treatment. Incubation of endothelial cells with oxidized LDL (OxLDL) or lysolecithin resulted in decreased matrix proteoglycans and increased Lp(a) retention by matrix. The effect of OxLDL or lysolecithin on endothelial PG was abolished in the presence of HDL. The decrease in matrix **HSPG** was associated with production of a heparanase-like activity by OxLDL-stimulated endothelial cells. To test whether removal of **HSPG** exposes fibronectin, a candidate Lp(a) binding protein in the matrix, antifibronectin antibodies were used. The increased Lp(a) binding after **HSPG** removal was inhibited 60% by antifibronectin antibodies. Similarly, the increased Lp(a) binding to matrix from OxLDL-treated endothelial cells was inhibited by antifibronectin antibodies. We hypothesize that atherogenic lipoproteins stimulate endothelial cell production of heparanase. This enzyme reduces **HSPG** which in turn promotes Lp(a) retention.

AU **Pillarisetti, Sivaram** [Reprint author]; Paka, Latha; Obunike, Joseph C.; Berglund, Lars; Goldberg, Ira J.

AB. . . and proteoglycans, has important roles in lipid and lipoprotein retention and cell adhesion. In atherosclerosis, vessel wall heparan sulfate proteoglycans (**HSPG**) are decreased and we therefore tested whether selective loss of **HSPG** affects lipoprotein retention. A matrix synthesized by aortic endothelial cells and a commercially available matrix (Matrigel; Becton Dickinson Inc., Rutherford,. . . LDL binding by apprx 1.5-fold. Binding of lipoprotein (a) (Lp(a)) to both subendothelial matrix and Matrigel increased 2-10-fold when the **HSPG** were removed by heparinase treatment. Incubation of endothelial cells with oxidized LDL (OxLDL) or lysolecithin resulted in decreased matrix proteoglycans. . . The effect of OxLDL or lysolecithin on endothelial PG was abolished in the presence of HDL. The decrease in matrix **HSPG** was associated with production of a heparanase-like activity by OxLDL-stimulated endothelial cells. To test whether removal of **HSPG** exposes fibronectin, a candidate Lp(a) binding protein in the matrix, antifibronectin antibodies were used. The increased Lp(a) binding after **HSPG** removal was inhibited 60% by antifibronectin antibodies. Similarly, the increased Lp(a) binding to matrix from OxLDL-treated endothelial cells was inhibited by antifibronectin

US 1076341305P1

Creation date: 11-30-2004
Indexing Officer: NKIDANE - NIGIST M. KIDANE
Team: OIPEScanning
Dossier: 10763413

Legal Date: 11-30-2004

No.	Doccode	Number of pages
1	CTRS	7
2	BIB	1
3	FWCLM	1

Total number of pages: 9

Remarks:

Order of re-scan issued on .....